Skip to main content
. 2020 Aug 11;11(32):3048–3060. doi: 10.18632/oncotarget.27694

Figure 1. Tumor growth and overall survival.

Figure 1

Tumor growth assessment: data for each time-point in mm3 are mean ± SEM. (A) M-234p, N = 6/group; Day 21: Control (600.96 ± 93) vs Cy+Los (20.96 ± 9.01) (P < 0.05); (B) M-406, N = 6–7/group; Day 17: Control (1397.00 ± 328.32) vs Cy (372.00 ± 55.25) (P < 0.01), vs Los (451.07 ± 143.94) (P < 0.05), vs Cy+Los (123.43 ± 45.71) (P < 0.001). Kruskal-Wallis multiple comparison test and Dunn’s post-test. Overall survival (Kaplan-Meier), Median Survival (MS): (C) M-234p, N = 5–6/group; Control (MS: 34 days); Cy (MS: 47 days); Los (MS: 32 days); Cy+Los (MS: undefined, Day 32: 60% [3/5] complete tumor regressions). Cy+Los vs Control, vs Los, vs Cy (P < 0.01); (D) M-406, N = 6–7/group); Control (MS: 24 days); Cy (MS: 36.5 days); Los (MS: 33 days); Cy+Los (MS: 47 days). Control vs Cy (P < 0.01), vs Los (P < 0.01), vs Cy+Los (P < 0.001); Cy+Los vs Cy (P < 0.05), vs Los (P < 0,001). Log-rank Test.